A 45-year-old woman with type 2 diabetes mellitus presents with blurred vision and reports seeing a halo around lights. Slit-lamp examination reveals a true posterior subcapsular cataract with early anterior swelling. She is keen to delay surgery. Which medication is the drug of choice for slowing progression of her diabetic cataract?

Explanation

## Medical Management of Diabetic Cataracts ### Pathophysiology of Diabetic Cataract Formation Diabetic cataracts—particularly posterior subcapsular and true diabetic cataracts—develop via the **polyol pathway**: 1. Hyperglycemia → glucose enters lens via GLUT1 transporter 2. Aldose reductase converts glucose → sorbitol 3. Sorbitol accumulates (cannot cross lens capsule) → osmotic stress 4. Water influx → lens fiber swelling and disruption 5. Sorbitol → fructose → advanced glycation end-products (AGEs) 6. Protein cross-linking and opacity **Key Point:** Aldose reductase inhibitors block the rate-limiting first step of the polyol pathway, preventing sorbitol accumulation and slowing cataract progression. ### Aldose Reductase Inhibitors (ARIs) **High-Yield:** Epalrestat is the most widely studied and clinically used ARI in ophthalmology practice, particularly in Asia and India. **Mechanism:** - Competitively inhibits aldose reductase - Reduces sorbitol accumulation in the lens - Slows osmotic stress and protein denaturation - Delays progression of posterior subcapsular and true diabetic cataracts by 6–12 months in prospective trials **Dosing & Route:** - Oral: 50 mg three times daily (most common) - Topical formulations also available but less effective than systemic therapy **Clinical Pearl:** ARIs are most effective in early-stage diabetic cataracts (posterior subcapsular, true diabetic) and show less benefit in advanced nuclear sclerotic cataracts. Tight glycemic control remains the cornerstone of prevention. ### Why Other Options Fail | Agent | Mechanism | Why Not for Diabetic Cataract | |-------|-----------|------------------------------| | Dorzolamide (carbonic anhydrase inhibitor) | Aqueous humor suppression | Used for glaucoma; no role in cataract pathophysiology | | Betamethasone (topical corticosteroid) | Anti-inflammatory | May worsen cataract progression; steroids can induce cataracts with chronic use | | Metformin (biguanide) | Glycemic control | Essential for diabetes management but does not specifically block polyol pathway; indirect benefit only | **Warning:** Do not confuse glycemic control agents (metformin, insulin) with **specific anti-cataract agents** (ARIs). While tight glucose control is fundamental to preventing all diabetic complications, ARIs directly target the lens-specific polyol pathway. ### Mnemonic for Diabetic Cataract Drugs **"SORBI-STOP"** — **S**orbitol **O**utput **R**educed **B**y **I**nhibiting **S**orbitol-producing enzyme (**A**ldose **R**eductase) = **STOP** cataract **P**rogression.